COMPANY

Amplexd Therapeutics

Amplexd Therapeutics is developing investigational platform technologies for localized infectious disease and cancer interception, starting with human papillomavirus (HPV)-associated precancer. From company website Source · Oct 12, 2026

Keywords: infectious disease High-risk HPV (Any Strain) LSIL, Low Grade Squamous Intraepithelial Lesion ASC-US HPV Infection Cervical Abnormalities Uterine Cervical Dysplasia

Profile checked Oct 10, 2026

1Trials (company is sponsor)

Timeline

Apr 30, 2026 Trial start II: Phase II Study of Dysplasix™ Intravaginal Suppositories in Patients Patients With High-Risk HPV and Mild Cervical Cytologic Abnormalities source ↗

Upcoming milestones

Dec 27, 2026 (ESTIMATED) · II · Phase II Study of Dysplasix™ Intravaginal Suppositories in Patients Patients With High-Risk HPV and Mild Cervical Cytologic Abnormalities · NCT07572396

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 1

Record	Title	Phase	Status	Start	Primary completion
NCT07572396	Phase II Study of Dysplasix™ Intravaginal Suppositories in Patients Patients With High-Risk HPV and Mild Cervical Cytologic Abnormalities	II	Recruiting	Apr 30, 2026	Dec 27, 2026 (estimated)